https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/accelerated-approval-granted-drug-developed-gosh/
Accelerated approval granted for drug developed at GOSH
14 Dec 2016, 9:55 a.m.
The United States Food and Drug Administration (FDA) granted accelerated approval for a new medication to treat Duchenne muscular dystrophy (DMD). The drug, Eteplirsen, was developed by a UK consortium led by Novel Therapies Theme lead, Professor Francesco Muntoni.
DMD is a severe, muscle-wasting condition caused by a fault in a gene, resulting in a failure to produce functional dystrophin. Currently DMD has few treatment options.
Eteplirsen was filed by Sarepta Therapeutics for accelerated approval by the FDA and is planned for immediate clinical use in the US. The approval for use in the EU is still underway. The drug will be used to treat patients with a specific subset of mutations of the dystrophin gene that affects around 13% of boys with DMD.
The drug ‘skips’ a part of the gene that makes dystrophin, which results in a shortened form of the dystrophin protein being produced, alleviating some of the symptoms of DMD and potentially extending a patient's mobility for a longer period of time.
New hope to prevent blindness in children with rare genetic disease
A new treatment that could prevent blindness in children with the CLN2 type Batten disease has been trialled by Clinicians at GOSH and University College London Great Ormond Street Institute of Child Health (UCL GOS ICH).
New clinical trial at GOSH gives hope to children with aggressive blood cancer
Researchers at GOSH and UCL Great Ormond Street Institute of Child Health (UCL GOS ICH) are collaborating on a novel approach to clinical trials to give hope to children with an aggressive type of blood cancer, T-cell acute lymphoblastic leukaemia (T-ALL)
Important step forward in stem cell therapy for rare bowel disease
A new study led by researchers at UCL Great Ormond Street Institute of Child Health (UCL GOS ICH) and the Centre for Stem Cell Biology, University of Sheffield, has demonstrated the potential of stem cell therapy to treat those with Hirschsprung disease.
First UK trial of Deep Brain Stimulation for children with epilepsy begins at GOSH
Discover how Oran became the first UK patient in a clinical trial using deep brain stimulation (DBS) for epilepsy. Learn about his 80% reduction in daytime seizures thanks to this innovative DBS treatment.